Pfizer/$PFE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Pfizer
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndamax and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
- Ticker
- $PFE
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 75,000
- Headquarters
- New York, United States
- Website
- www.pfizer.com
Pfizer Metrics
BasicAdvanced
$173B
40.03
$0.76
0.28
$1.72
5.65%
Price and volume
Market cap
$173B
Beta
0.28
52-week high
$30.44
52-week low
$23.62
Average daily volume
31M
Dividend rate
$1.72
Financial strength
Current ratio
1.267
Quick ratio
0.854
Long term debt to equity
0.711
Total debt to equity
0.743
Dividend payout ratio (TTM)
225.77%
Interest coverage (TTM)
6.98%
Profitability
EBITDA (TTM)
25,383
Gross margin (TTM)
74.72%
Net profit margin (TTM)
6.80%
Operating margin (TTM)
29.58%
Effective tax rate (TTM)
-3.89%
Revenue per employee (TTM)
$850,000
Management effectiveness
Return on assets (TTM)
5.78%
Return on equity (TTM)
5.01%
Valuation
Price to earnings (TTM)
40.033
Price to revenue (TTM)
2.718
Price to book
2.04
Price to tangible book (TTM)
-5.21
Price to free cash flow (TTM)
15.758
Free cash flow yield (TTM)
6.35%
Free cash flow per share (TTM)
1.93
Dividend yield (TTM)
5.65%
Forward dividend yield
5.65%
Growth
Revenue change (TTM)
-0.21%
Earnings per share change (TTM)
-59.88%
3-year revenue growth (CAGR)
-6.70%
10-year revenue growth (CAGR)
1.99%
3-year earnings per share growth (CAGR)
-41.30%
10-year earnings per share growth (CAGR)
-3.88%
3-year dividend per share growth (CAGR)
2.02%
10-year dividend per share growth (CAGR)
4.02%
What the Analysts think about Pfizer
Analyst ratings (Buy, Hold, Sell) for Pfizer stock.
Analyst projections of the future price of Pfizer stock.
Bulls say / Bears say
In Q2, non-COVID sales grew 5% operationally and launched and acquired products grew 18%, helping Pfizer raise the midpoint of its 2026 revenue outlook by $500 million. This suggests its newer portfolio is starting to offset weaker pandemic-product sales. (Pfizer)
Recent FDA approvals have widened the reach of established cancer medicines: Padcev with Keytruda can now be used before and after surgery for a broader group of bladder-cancer patients, while Tukysa gained a frontline maintenance use in HER2-positive metastatic breast cancer. These new uses could support further sales from Pfizer’s oncology portfolio. (Pfizer, Pfizer)
Pfizer reported encouraging Phase 2b results for its investigational monthly GLP-1 obesity drug and plans to advance it into 10 Phase 3 studies in 2026. Success could give Pfizer a foothold in a large growth market, though the medicine remains in development. (SEC)
Pfizer cut its 2026 COVID-product revenue expectation to about $4 billion from $5 billion. Its revised full-year revenue range of $60.5–$62.5 billion is still roughly flat or lower than 2025 sales of $62.6 billion. (CNBC)
Generic and biosimilar competition is expected to reduce 2026 revenue by about $1.1 billion, with further patent expirations putting pressure on established products. Newer medicines must grow enough to replace those sales. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 14 Oct 2026.
Pfizer Financial Performance
Revenues and expenses
Pfizer Earnings Performance
Company profitability
Upcoming events
Pfizer News
AllArticlesVideos
Funds containing Pfizer
AllEURUSDGBP
Fund name | Fund size | $PFE weighting |
|---|---|---|
VanEck Morningstar Developed Markets Dividend Leaders£TDGB | €9B | 4.60% |
VanEck Morningstar Developed Markets Dividend Leaders€TDIV | €9B | 4.60% |
Invesco S&P 500 High Dividend Low Volatility$HDLV | $456M | 3.81% |
Invesco S&P 500 High Dividend Low Volatility£HDLG | $456M | 3.81% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 2.62% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.